Inverse Association of Dietary Consumption of n3 and n6 Fatty Aids with Hyperuricemia among Adults

doi:10.21203/rs.3.rs-2976133/v1

Download PDF

Research Article

Inverse Association of Dietary Consumption of n3 and n6 Fatty Aids with Hyperuricemia among Adults

https://doi.org/10.21203/rs.3.rs-2976133/v1

This work is licensed under a CC BY 4.0 License

Version 1

posted

You are reading this latest preprint version

Background

The precise link between dietary consumption of n-3 and n-6 fatty acids and hyperuricemia remains equivocal. Accordingly, the purpose of the current investigation is to clarify any possible associations between the consumption of n-3 and n-6 fatty acids and hyperuricemia in the context of American adults.

Materials and methods

The present investigation employed a cross-sectional design, comprising a sample of 21,120 American adults above the age of 20 from the National Health and Nutrition Examination Survey (NHANES) waves between 2007 and 2016. The dietary consumption of n-3 and n-6 fatty acids was measured through two 24-h dietary recall interviews. To assess the relationships of dietary consumption of n3 and n6 fatty acids with hyperuricemia, we applied multivariable logistic regression, t tests, chi-square tests, and restricted cubic spline. To determine the robustness of our findings, sensitivity analyses were also carried out.

Results

The results of the multivariable logistic regression models indicated a significant correlation between dietary consumption of n3 and n6 fatty acids and hyperuricemia. The ORs with 95% CIs of hyperuricemia for the highest tertile versus lowest tertile of dietary consumption of n3 and n6 fatty acids were 0.76 (0.66, 0.88) (p < 0.001) and 0.72 (0.64, 0.82) (p < 0.001), respectively. Moreover, dose‒response analyses revealed a linear relationship between n-3 and n-6 fatty acid consumption and the risk of hyperuricemia.

Conclusion

The findings of this study indicate a significant inverse correlation between the dietary consumption of n3 and n6 fatty acids and hyperuricemia in the US adult population. Notably, there was no significant relationship between the n6:n3 ratio and hyperuricemia.

hyperuricemia

n3 fatty acids

n6 fatty acids

n6: n3 ratio

dose‒response

NHANES

Uric acid is the end-product of purine metabolism, and an elevation in serum uric acid levels beyond the normal range results in hyperuricemia. Extant research has highlighted the association between hyperuricemia and heightened risks of gout, as well as several other deleterious conditions, such as cardiovascular disease, metabolic syndrome, chronic kidney disease, type 2 diabetes, and lipid metabolism disorders [1–3]. Presently, hyperuricemia is emerging as a significant public health challenge, with epidemiological data revealing an escalating trend in the incidence of hyperuricemia and gout in Western countries [1, 4]. Consequently, there is a pressing need to explore modifiable risk factors associated with hyperuricemia to manage serum uric acid concentrations.

N-3 fatty acids represent polyunsaturated fatty acids that have the first double bond at the third carbon atom from the methyl end, while N-6 fatty acids have the first double bond at the sixth carbon atom[5]. Linoleic acid (LA) (n-6) and α-linolenic acid (ALA) (n-3) are considered essential fatty acids since they cannot be produced by humans or other higher animals. [6]. Previous studies have reported a correlation between dietary consumption of n3 and n6 fatty acids and the possibility of developing metabolic syndrome [7–9], cardiovascular diseases[10], obesity, cancer[7, 11], type 2 diabetes and gestational diabetes[12–14]. Meanwhile, several studies indicated that n3 and n6 fatty acids might decrease the level of serum uric acid[15, 16], while another study showed no relationship between n3, n6 and serum uric acid levels [17]. In addition, no studies reported a dose‒response relationship.

Given the inconsistencies in previous research findings, we made use of data from the National Health and Nutrition Examination Survey (NHANES) from 2007 to 2016 in this investigation to explore the relationships between the consumption of n3 and n6 fatty acids, as well as n6:n3 ratios, and the risk of hyperuricemia.

Study population

NHANES is a survey program initiated by the Centers for Disease Control and Prevention of America that gathers detailed information on the population's nutritional status and health twice a year. NHANES uses a complex multistage stratified probability cluster sampling technique to obtain a representative sample of noninstitutionalized civilians. The NHANES database is accessible to everyone in the world. The National Center for Health Statistics Research Ethics Review Board approved the current investigation, and all subjects provided written informed consent[5].

In this study, we analyzed publicly available data from five successive cycles of NHANES (2007–2008, 2009–2010, 2011–2012, 2013–2014, 2015–2016). We first identified 50588 participants in the database and subsequently developed the following exclusion criteria: a) younger than 20 years old, n = 21387; b) lack of complete uric acid reading, n = 2846; c) unreliable 24-h dietary recall data, n = 4756; d) missing weight data, n = 171; e) pregnant or lactating, n = 202; f) females with total energy intake < 500 or > 5000 kcal/day and males with < 500 or > 8000 kcal/day. Ultimately, this study enrolled 21120 adult participants (Fig. 1).

Serum uric acid measurement and definitions of hyperuricemia

A Beckman UniCel® DxC800 Synchron or a Beckman Synchron LX20 (Beckman Coulter, Inc., Brea, CA, USA) was used to measure uric acid concentrations in serum, plasma, or urine with a timed endpoint approach. Allantoin and hydrogen peroxide are created when uricase oxidizes uric acid, and the latter is then used in a reaction catalyzed by peroxidase with 4-aminoantipyrine (4-AAP) and 3,5-dichloro-2-hydroxybenzene sulfonate (DCHBS). The system monitors changes in absorbance at 520 nm at predetermined intervals to determine whether a colored product has been produced by this reaction. The amount of uric acid in the sample directly correlates to the change in absorbance. Serum uric acid levels of > 6.0 mg/dL for women and > 7.0 mg/dL for men were defined as hyperuricemia. [18].

The dietary consumption of n3 and n6 fatty acids

N3 and N6 fatty acid intake data were gathered from two 24-hour dietary recall interviews [19]. The interviews took place face-to-face at the mobile examination center (MEC) and then over the phone three to ten days later. Alpha-linolenic acid (ALA), stearidonic acid (SDA), docosapentaenoic acid (DPA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) are all members of the n3 fatty acid group. Linoleic acid (18:2) and arachidonic acid (20:4) are both members of the n6 fatty acid group. Based on the Dietary Research Food and Nutrition Database for Dietary Studies maintained by the U.S. Department of Agriculture, the average daily consumption of n3 and n6 fatty acids was computed and weighed. Tertiles were created based on dietary n3 and n6 fatty acid consumption as well as the n6:n3 ratio.

Covariates

To account for potential confounders, a number of covariates were chosen based on previous research. Potential confounders in the demographic variables are as follows: a) age (20–40 years, 40–60 years, and ≥ 60 years), b) sex (male and female), c) ethnicity (Mexican American, Other Hispanic, Non-Hispanic White, Non-Hispanic Black, and Other ethnicities), d) educational level (below high school, high school, and above high school), e) marital status (married/living with partner and widowed/divorced/separated/never married), f) annual household income (<$20,000 and ≥$20,000), g) body mass index (< 25.0 kg/m2, 25.0 to 30.0 kg/m2 and ≥ 30.0 kg/m2), h) hypertension status (yes/no), i) smoking status (ever smoked ≥ 100 cigarettes in life or not), j) drinking status (having at least 12 alcohol drinks per year or not), k) work activity (vigorous activity, moderate activity, and other), l) recreational activity (vigorous activity, moderate activity, and other), m) diabetes (yes/no), and n) total cholesterol (TC) and high-density lipoprotein cholesterol (HDL-C). Self-reported diabetes history was used to define diabetes. Hypertension was defined as the use of antihypertensive medications, a mean systolic blood pressure > 130 mmHg or a mean diastolic blood pressure < 80 mmHg.

Statistical analysis

The normality of continuous variables was examined with Kolmogorov‒Smirnov tests. [20]. The mean ± standard deviation was used to express normally distributed variables. The differences between the hyperuricemia group and the nonhyperuricemia group were compared using t tests or chi-square testing depending on the characteristics of the variables. Tertiles were used to group the adjusted dietary consumption of n3 and n6 fatty acids and the n6:n3 ratio. We set tertile 1 as the reference group. The connection of the consumption of n3 and n6 fatty acids as well as the n6:n3 ratio with hyperuricemia was examined using multivariable logistic regression models. For ethnicity, sex, and age, Model 1 was modified. Additional adjustments were made in Model 2 for factors such as education level, marital status, annual household income, BMI, hypertension, drinking and smoking habits, work and recreational activity, diabetes, TC, HDL-C, and TG. To further explore the relationship between dietary n3 and n6 fatty acid intake and the risk of hyperuricemia, we performed stratified analyses by sex and age. With three knots placed at the 5th, 50th, and 95th percentiles of the exposure distribution, we used restricted cubic splines (RCS) to analyze the dose‒response relationship. The confounding factors that were addressed in multivariate-adjusted Model 2 were also adjusted in the restricted cubic spline. We modeled the median values of each tertile as a continuous variable in the overall models to examine the trend across tertiles of daily dietary consumption of n3 and n6 fatty acids and the n6:n3 ratio. Because kidney diseases and obesity may affect the result[21], we further conducted sensitivity analyses to estimate the robustness of our study by excluding participants with obesity (BMI ≥ 30 kg/m²) and significant renal dysfunction (eGFR lower than 60 mL/min/1.73 m²). Testing the value of the coefficient for zero of the second spline resulted in the calculation of the p value for nonlinearity. In our investigations, a nationally representative estimate was produced using the appropriate sampling weights, primary sampling unit, and stratum information. Stata 14.0 (Stata Corporation, College Station, Texas, USA) was used to conduct each statistical analysis. Statistical significance was defined as a two-sided p < 0.05.

1, Baseline characteristics

The characteristics of NHANES participants with hyperuricemia are presented in Table 1. Among 21,120 participants, the prevalence of hyperuricemia was 19.5%. Compared with the nonhyperuricemia group, people with hyperuricemia tended to be male, have non-Hispanic white and black ethnicity, have lower household income and educational level, have age more than 60 years old, have diabetes and hypertension, live alone, smoke more, have lower recreation activity, and have higher BMI, TG, and TC. In addition, the total adjusted consumption of n3 and n6 fatty acids in hyperuricemia was significantly lower in participants without hyperuricemia.

Table 1

Characteristics of National Health and Nutrition Examination Survey (NHANES) participants by hyperuricemia
	Non-Hyperuricemia	Hyperuricemia	P Value
Number of Participants (%)	16,820(80.5)	4,300 (19.5)
Age group (%)¹			< 0.01
20–40 years	5,721 (35.4)	1,035 (27.75)
40–60 years	5,891 (39.6)	1,305 (35.99)
≥60 years	5,208 (25.0)	1,960 (36.25)
Gender (%)¹			< 0.01
Male	7906(46.3)	2316(55.5)
Female	8914(53.7)	1984(44.5)
Ethnicity (%)¹			< 0.01
Non-Hispanic White	7360(68.8)	2072(72.6)
Non-Hispanic Black	3213(10.0)	1047(11.8)
Mexican American	2693(8.6)	467(5.8)
Other Hispanic	1897(5.8)	327(3.7)
Other ethnicities	1657(6.8)	387(6.1)
Educational level (%)¹
Below high school	3973(15.5)	1020(15.9)	0.0308
High school	3759(21.6)	1047(24.2)
Above high school	9074(62.9)	2229(62.3)
Marital status (%)¹			< 0.01
Married/Living with partner	10,243(65.3)	2,457(62.1)
Widowed/Divorced/Separated/Never married	6,571(34.7)	1,843(37.9)
Household income (%)¹			< 0.01
<$20,000	3,245(13.2)	987(15.4)
≥$20,000	12,854(86.8)	3,141(84.6)
Body mass index (%)¹			< 0.01
< 25 kg/m²	5332(33.2)	569(12.7)
25 to < 30 kg/m²	5776(34.6)	1236(29.3)
≥ 30 kg/m²	5688(32.2)	2483(58.1)
Hypertension (%)¹			< 0.01
Yes	8884(58.0)	2935(64.6)
No	7658(42.0)	1317(35.4)
Smoking at least 100 cigarettes in life (%)¹			< 0.01
Yes	7322(46.6)	2084(48.1)
No	9490(56.4)	2214(51.9)
Have at least 12 alcohol drinks/year (%)¹			0.631
Yes	11,492(77.6)	2,985(77.2)
No	4404(22.4)	1145(22.8)
Recreation activity (%)¹			< 0.01
Vigorous activity	3858(27.2)	672(18.7)
Moderate activity	4515(28.7)	1151(29.8)
Other	8447(44.1)	2477(51.6)
Work activity (%)¹			0.370
Vigorous activity	3172(20.5)	808(20.6)
Moderate activity	3641(23.6)	930(25.0)
Other	15,930(55.9)	2562(54.4)
Diabetes (%)¹			< 0.01
Yes	1904(8.5)	794(14.8)
No	14559(91.5)	3366(85.2)
Total energy intake (kcal/day)²	2038.5(801.0)	1971.0(786.3)	< 0.01
TC (mg/dL)²	192.4(41.1)	197.4(43.2)	< 0.01
HDL-C (mg/dL)²	53.8(16.1)	48.9(15.3)	< 0.01
TG (mg/dL)²	148.8(133.1)	185.1(145.9)	< 0.01
Total adjusted n3 fatty acid intake (mg/kg/day)²	23.1(14.9)	19(13.5)	< 0.01
Total adjusted n6 fatty acid intake (mg/kg/day)²	204.1(116.4)	172(100.9)	< 0.01
n6: n3 ratio²	9.5(3.4)	9.4(3.2)	0.264
Data are the number of subjects (percentage) or mean (standard deviation).
¹Number of participants and weighted percentage. Chi-square test was used to compare the percentage between participants with and without hyperuricemia. ²Weighted mean value and standard deviation (SD). Student’s t-test was used to compare the mean values between participants with and without hyperuricemia. National Health and Nutrition Examination Survey (NHANES).

2, Associations between dietary consumption of n3 and n6 fatty acids and hyperuricemia

Table 2 displays odds ratios (ORs) and 95% confidence intervals (CIs) for hyperuricemia based on tertiles of adjusted dietary consumption of n3 and n6 fatty acids and the n6:n3 ratio. Compared with the lowest tertile, the highest tertile of dietary consumption of n3 and n6 fatty acids was linked to a lower prevalence of hyperuricemia in the binary logistic regression analysis, with ORs of 0.50 (95% CI: 0.45, 0.56) and 0.49 (95% CI: 0.45, 0.54), respectively. However, no significant association was found between the n6:n3 ratio and the risk of hyperuricemia in any model. After adjusting for age, sex, and ethnicity (Model 1), dietary consumption of n3 and n6 fatty acids remained significantly associated with a decreased prevalence of hyperuricemia. Furthermore, after additional adjustments for educational level, marital status, annual household income, hypertension, smoking status, work activity, recreational activity, diabetes, BMI, TC, HDL-C, and TG (Model 2), the ORs (95% CIs) for hyperuricemia for dietary consumption of n-3 and n-6 fatty acids were 0.76 (0.66, 0.88) and 0.72 (0.64, 0.82), respectively.

Table 2

Weighted odds ratios (95% confidence intervals) of hyperuricemia across tertiles of adjusted dietary n3, n6 fatty acid intake and n6: n3 ratio
	Case/Participants	Crude1 OR (95% CI)		Model 1 OR (95% CI)
Adjusted n3 (mg/kg/day)
< 14.89	1,817/7,027		1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
14.89 to 24.48	1,423/7,039	0.72(0.65,0.80)		0.73(0.65,0.81)	0.88(0.78,1.00)
≥ 24.48	1,060/7,054	0.50(0.45,0.56)		0.49(0.44,0.56)	0.76(0.66,0.88)
Adjusted n6 (mg/kg/day)
< 136.71	1,840/7,033		1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
136.71 to 220.81	1,399/7,034		0.71(0.63,0.79)	0.70(0.62,0.78)	0.84(0.75,0.95)
≥ 220.81	1,061/7,053		0.49(0.45,0.54)	0.48(0.43,0.53)	0.72(0.64,0.82)
n6: n3 ratio
< 8.07	1,432/7,043		1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
8.07 to 9.94	1,461/7,012		1.08(0.97,1.20)	1.09(0.98,1.22)	1.02(0.91,1.15)
≥ 9.94	1,407/7,065		0.98(0.88,1.09)	0.99(0.88,1.10)	0.93(0.82,1.06)

Model 1 adjusted for age, gender, ethnicity.

Model 2 further adjusted for educational level, marital status, annual household income, body mass index (BMI), hypertension, smoking status, work activity, recreational activity, diabetes, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and total triglycerides (TG). The lowest tertile of dietary n3, n6, n6: n3 intake was used as the reference group.

3, Consumption of N3 and n6 fatty acids stratified by age

Table 3 presents the associations between dietary consumption of n3 and n6 fatty acids and hyperuricemia risk stratified by age. After adjusting for age, sex, ethnicity, educational level, marital status, annual household income, hypertension, smoking status, work activity, recreational activity, diabetes, BMI, TC, HDL-C, and TGs (Model 2), the ORs (95% CIs) of hyperuricemia among participants aged 20 to 40 were 0.61 (0.48, 0.77) for dietary n3 fatty acid intake and 0.68 (0.56, 0.84) for dietary n6 fatty acid intake. For those aged 40–60 years old, the ORs (95% CIs) of n3 and n6 fatty acid intake in Model 2 were 0.74 (0.58, 0.96) and 0.62 (0.50, 0.76), respectively. However, among participants aged over 60 years old, no significant association was found between dietary consumption of n3 and n6 fatty acids and the risk of hyperuricemia (Model 2). Additionally, the link between the n6:n3 ratio and the risk of hyperuricemia was not significant in any of the subgroup analyses.

Table 3

The ORs (95%CIs) of hyperuricemia by adjusted dietary n3, n6 fatty acid intake and n6: n3 ratio
	20 ≤ Age < 40 Years (n = 6,756)			40 ≤ Age < 60 Years (n = 7,196)
	Crude OR (95% CI)	Model 1 OR (95% CI)	Model 2 OR (95% CI)	Crude OR (95% Cl)	Model 1 OR (95% CI)	Model 2 OR (95% CI)	Crude OR (95% CI)	Model 1 OR (95% CI)	Model 2 OR (95% CI)
Adjusted n3 (mg/kg/day)
< 14.89	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
14.89 to 24.48	0.77	0.70	0.91	0.71	0.70	0.82	0.73	0.73	0.87
14.89 to 24.48	(0.65,0.90)	(0.60,0.82)	(0.75,1.09)	(0.58,0.88)	(0.57,0.86)	(0.65,1.04)	(0.61,0.87)	(0.61,0.88)	(0.72,1.06)
≥ 24.48	0.40	0.35	0.61	0.53	0.51	0.74	0.59	0.60	0.88
≥ 24.48	(0.33,0.48)	(0.29,0.43)	(0.48,0.77)	(0.42,0.66)	(0.41,0.64)	(0.58,0.96)	(0.50,0.70)	(0.50,0.71)	(0.71,1.09)
Adjusted n6 (mg/kg/day)
< 136.71	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
136.71 to 220.81	0.74	0.67	0.90	0.70	0.68	0.78	0.71	0.72	0.85
136.71 to 220.81	(0.62,0.88)	(0.56,0.81)	(0.73,1.10)	(0.58,0.84)	(0.57,0.82)	(0.64,0.96)	(0.59,0.86)	(0.60,0.88)	(0.70,1.04)
≥ 220.81	0.45	0.38	0.68	0.49	0.46	0.62	0.58	0.59	0.86
≥ 220.81	(0.38,0.54)	(0.32,0.46)	(0.56,0.84)	(0.42,0.59)	(0.39,0.55)	(0.50,0.76)	(0.50,0.69)	(0.51,0.70)	(0.70,1.05)
n6: n3 ratio
< 8.07	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
8.07 to 9.94	1.03	1.00	0.98	1.11	1.08	1.05	1.18	1.19	1.02
8.07 to 9.94	(0.85,1.25)	(0.82,1.23)	(0.78,1.23)	(0.89,1.37)	(0.87,1.34)	(0.83,1.32)	(1.00,1.41)	(1.00,1.41)	(0.85,1.23)
≥ 9.94	1.08 (0.88,1.32)	1.02	1.00	0.99	0.94	0.89	1.05	1.05	0.97
≥ 9.94	1.08 (0.88,1.32)	(0.83,1.25)	(0.82,1.22)	(0.80,1.23)	(0.75,1.17)	(0.69,1.14)	(0.88,1.26)	(0.88,1.26)	(0.80,1.19)

Model 1 adjusted for age, gender, ethnicity.

4, Consumption of N3 and n6 fatty acids stratified by sex

In Table 4, the correlations between dietary consumption of n3 and n6 as well as the n6:n3 ratio and the risk of hyperuricemia stratified by sex are displayed. In males, after adjusting for confounders (Model 2), the ORs (95% CIs) for hyperuricemia were 0.75 (0.63, 0.90) and 0.69 (0.59, 0.80) for consumption of n3 and n6 fatty acids, respectively. Similar associations were observed in females. However, there was no statistically significant relationship between the incidence of hyperuricemia and the n6:n3 ratio in any of the subgroup analyses.

Table 4

The ORs (95%CIs) of hyperuricemia by adjusted dietary n3, n6 fatty acid intake and n6: n3 ratio, stratified by gender
	Men (n = 10,222)			Women (n = 10,898)
	Crude OR (95% CI)	Model 1 OR (95% CI)	Model 2 OR (95% CI)	Crude OR (95% CI)	Model 1 OR (95% CI)	Model 2 OR (95% CI)
Adjusted n3 (mg/kg/day)
< 14.89	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
14.89 to 24.48	0.79(0.69,0.90)	0.79(0.69,0.91)	0.93(0.79,1.10)	0.64(0.57,0.72)	0.64(0.56,0.72)	0.79(0.69,0.92)
≥ 24.48	0.53(0.45,0.61)	0.53(0.45,0.61)	0.75(0.63,0.90)	0.45(0.37,0.54)	0.44(0.36,0.54)	0.73(0.59,0.90)
Adjusted n6 (mg/kg/day)
< 136.71	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
136.71 to 220.81	0.68(0.58,0.81)	0.68(0.57,0.80)	0.78(0.65,0.93)	0.70(0.61,0.82)	0.72(0.62,0.83)	0.90(0.76,1.06)
≥ 220.81	0.51(0.45,0.58)	0.50(0.44,0.58)	0.69(0.59,0.80)	0.42(0.35,0.51)	0.43(0.36,0.52)	0.71(0.58,0.87)
n6: n3 ratio
< 8.07	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)	1.00 (Ref.)
8.07 to 9.94	1.15(0.97,1.36)	1.14(0.96,1.35)	1.07(0.89,1.28)	0.99(0.87,1.13)	1.05(0.91,1.21)	0.95(0.80,1.13)
≥ 9.94	1.04(0.89,1.22)	1.02(0.87,1.20)	0.97(0.81,1.15)	0.88(0.74,1.04)	0.97(0.81,1.18)	0.91(0.73,1.13)

Model 1 adjusted for age, gender, ethnicity.

5, Sensitivity analyses

We further performed sensitivity analysis by excluding participants with obesity (BMI ≥ 30 kg/m²) and significant renal dysfunction (eGFR lower than 60 mL/min/1.73 m²). After fully adjusting for the same confounding factors, the highest tertiles for adjusted n3 and n6 intakes in all models were still negatively associated with the risk of hyperuricemia, and no significant conclusion was obtained between the n6:n3 ratio and the risk of hyperuricemia (Supplementary Table 1).

6, Dose‒response analyses

Figures 2 and 3 depict the dose‒response analyses between the consumption of n3 and n6 fatty acids and hyperuricemia. The intake of n3 fatty acids and hyperuricemia were found to be linearly correlated (P for nonlinearity = 0.0790). The prevalence of hyperuricemia decreased as the consumption of n3 fatty acids increased. Moreover, this linear inverse association between the consumption of n6 fatty acids and the prevalence of hyperuricemia was also detected (P for nonlinearity = 0.0766). Since there was no significant correlation found in the multivariable logistic regression (Model 2), a dose‒response analysis between the n6:n3 ratio and hyperuricemia was not carried out.

In this investigation, we indicated that the dietary consumption of n3 and n6 fatty acids was negatively correlated with the risk of hyperuricemia, while no significant association between the n6:n3 ratio and the possibility of hyperuricemia was found. Furthermore, the dose‒response analyses showed linear associations between the dietary consumption of n3 and n6 fatty acids and the risk of hyperuricemia.

To the best of our knowledge, this was the first investigation into the correlation between dietary intakes of n3, n6 and the ratio of n6 to n3 fatty acids and the risk of hyperuricemia in US adults using a nationally representative sample. The results of several previous studies were consistent with our findings. An in vitro cell experiment showed that unsaturated fatty acids, especially polyunsaturated fatty acids, could strongly inhibit urate transporter 1 (URAT1), which could reabsorb urate filtered by the glomerulus of the kidney from primary urine into the blood[16]. Akhigbe et al. found that n3 fatty acids decreased testicular uric acid significantly in Torsion/Detorsion rats[15]. However, contrary to our findings, a study comprising 113 participants who were 18 years of age and older at the Hospital of the Federal University of Uberlandia revealed no correlation between n-3 and n-6 fatty acids and blood uric acid[22]. The disparity could be explained by a number of things. First, when compared to that of our study (21,120 American adults), the sample of the above research was too small (113 American adults). Second, the participants in the earlier study were all kidney transplant patients, and their uric acid metabolism was abnormal because of kidney dysfunction.

Although the underlying mechanisms between dietary consumption of n3 and n6 fatty acids and the risk of hyperuricemia are not completely understood, several possibilities have been proposed. First, prior research revealed that n3 and n6 fatty acids were inversely connected to the incidence of hypertension and had a protective effect on defective endothelial cells and nitric oxide-dependent responses[23, 24]. Meanwhile, hypertension could elevate serum uric acid levels by increasing renal vascular resistance and uric acid retention[25]. Thus, n3 and n6 fatty acids might decrease susceptibility to hyperuricemia by lowering blood pressure. Second, polyunsaturated fatty acids could prevent and reverse insulin resistance[26, 27]. Insulin resistance increased serum uric acid levels by damaging urinary endothelial function and reducing uric acid excretion[28, 29]. Therefore, n3 and n6 fatty acids were likely inversely related to elevated serum uric acid levels because of their function of improving insulin resistance. To understand the mechanisms behind the link between dietary consumption of n-3 and n-6 fatty acids and the risk of hyperuricemia, more research is needed.

Previous research revealed that the intake of dairy products[30–32], vitamin C[33], vitamin D[34], soy products[35], dietary fiber[36], magnesium[37], and dietary zinc intake[38] were adversely connected to the incidence of hyperuricemia. Thus, dietary changes may be connected to hyperuricemia. Our findings showed that increased dietary polyunsaturated fatty acids might decrease the risk of hyperuricemia. In addition, green leafy vegetables, legumes, nuts, and seafood are all rich in polyunsaturated fatty acids[11, 39], and these foods are common in our daily meals. It is beneficial for individuals to maintain sufficient polyunsaturated fatty acid intake to prevent the risk of hyperuricemia.

When stratified by age, the dietary consumption of n3 and n6 fatty acids was associated with a nonsignificant lower risk of hyperuricemia among people aged 60 years old and above in the fully adjusted model. This may be explained by the high prevalence of hypertension among older adults. Some antihypertensive medications, such as loop and thiazide diuretics, cause relative hypovolemia, which induces a compensatory increase in proximal uric acid reabsorption[40], and approximately two-thirds of all uric acid is excreted by the kidneys[29].

Our study has several strengths. First, this was the first study to investigate the correlation between dietary n3 and n6 fatty acids and the susceptibility of hyperuricemia with their dose‒response relationship among US adults using the largest nationally representative sample (21,120 participants). Second, to lessen the impact of visceral fat accumulation and kidney on serum uric acid, we performed sensitivity analyses by removing subjects with obesity (BMI 30 kg/m2) and substantial renal dysfunction (eGFR lower than 60 mL/min/1.73 m2)[41, 42]. Third, the utilization of trained personnel who adhered to standardized protocols for measuring essential study data and conducting interviews enhanced the accuracy and efficiency of the data collection process.

Additionally, our study has some flaws. First, it is impossible to determine causality due to the cross-sectional design. Future studies utilizing longitudinal designs are necessary to confirm our findings. Second, two 24-hour food recall interviews were used to collect the dietary data, which may not have provided an accurate representation of long-term average intake. Third, our study did not take into account the intake of n3 and n6 fatty acids from dietary supplements, which could be an important source of these nutrients. Fourth, our study population was limited to Americans, and it is unclear whether our results can be generalized to other countries.

In conclusion, the findings of this study indicated that the dietary consumption of n3 and n6 fatty acids was inversely correlated with hyperuricemia in US adults, independent of some major confounding factors. The n6:n3 ratio was not shown to be significantly correlated with hyperuricemia. To support our findings, additional large-scale prospective studies using more precise dietary survey techniques are needed.

-Ethics approval and consent to participate.

The Ethics Review Board of the National Center for Health Statistics approved all NHANES protocols.

-Consent to publish

Not Applicable.

-Availability of data and materials

Publicly available datasets were analyzed in this study. This data can be found here: https://www.cdc.gov/nchs/nhanes/

-Competing interests

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

-Funding

This work was supported by the National Natural Science Foundation of China (grant no.81802337), Shanghai Jiao Tong University (grant no.YG2017MS74), and the Shanghai Health Committee (grant no. 2020404447).

-Acknowledgments

The authors appreciate the American Centers for Disease Control and Prevention for conducting the survey and making it available online freely, and all the participants for providing these data.

-Author contributions

Yuxin Sun had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Concept and design: Yuxin Sun and Fei Ma. Acquisition, analysis, and interpretation of data: Yuxin Sun, Chao Zhang, Xiangrong Xin, and Fei Ma. Drafting of the manuscript: Yuxin Sun, Chao Zhang, Xiangrong Xin, Haihong Yu, and Yue Lin. Critical revision of the manuscript for important intellectual content: Yuxin Sun, Chao Zhang, Xiangrong Xin. All authors have read and agreed to the published version of the manuscript.

Zhang S, Wang Y, Cheng J, Huangfu N, Zhao R, Xu Z, Zhang F, Zheng W, Zhang D: Hyperuricemia and Cardiovascular Disease. Curr Pharm Des 2019, 25(6):700-709.
Sluijs I, Beulens JW, van der AD, Spijkerman AM, Schulze MB, van der Schouw YT: Plasma uric acid is associated with increased risk of type 2 diabetes independent of diet and metabolic risk factors. J Nutr 2013, 143(1):80-85.
Keenan T, Blaha MJ, Nasir K, Silverman MG, Tota-Maharaj R, Carvalho JA, Conceição RD, Blumenthal RS, Santos RD: Relation of uric acid to serum levels of high-sensitivity C-reactive protein, triglycerides, and high-density lipoprotein cholesterol and to hepatic steatosis. Am J Cardiol 2012, 110(12):1787-1792.
Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK: Contemporary Prevalence of Gout and Hyperuricemia in the United States and Decadal Trends: The National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheumatol 2019, 71(6):991-999.
Ratnayake WM, Galli C: Fat and fatty acid terminology, methods of analysis and fat digestion and metabolism: a background review paper. Ann Nutr Metab 2009, 55(1-3):8-43.
Saini RK, Keum YS: Omega-3 and omega-6 polyunsaturated fatty acids: Dietary sources, metabolism, and significance - A review. Life Sci 2018, 203:255-267.
Martínez-Fernández L, Laiglesia LM, Huerta AE, Martínez JA, Moreno-Aliaga MJ: Omega-3 fatty acids and adipose tissue function in obesity and metabolic syndrome. Prostaglandins Other Lipid Mediat 2015, 121(Pt A):24-41.
Dasgupta Y, Golovine K, Nieborowska-Skorska M, Luo L, Matlawska-Wasowska K, Mullighan CG, Skorski T: Drugging DNA repair to target T-ALL cells. Leuk Lymphoma 2018, 59(7):1746-1749.
Yary T, Voutilainen S, Tuomainen TP, Ruusunen A, Nurmi T, Virtanen JK: Omega-6 polyunsaturated fatty acids, serum zinc, delta-5- and delta-6-desaturase activities and incident metabolic syndrome. J Hum Nutr Diet 2017, 30(4):506-514.
Del Gobbo LC, Imamura F, Aslibekyan S, Marklund M, Virtanen JK, Wennberg M, Yakoob MY, Chiuve SE, Dela Cruz L, Frazier-Wood AC et al: ω-3 Polyunsaturated Fatty Acid Biomarkers and Coronary Heart Disease: Pooling Project of 19 Cohort Studies. JAMA Intern Med 2016, 176(8):1155-1166.
D'Angelo S, Motti ML, Meccariello R: ω-3 and ω-6 Polyunsaturated Fatty Acids, Obesity and Cancer. Nutrients 2020, 12(9).
Brayner B, Kaur G, Keske MA, Livingstone KM: FADS Polymorphism, Omega-3 Fatty Acids and Diabetes Risk: A Systematic Review. Nutrients 2018, 10(6).
Jamilian M, Samimi M, Ebrahimi FA, Hashemi T, Taghizadeh M, Razavi M, Sanami M, Asemi Z: The effects of vitamin D and omega-3 fatty acid co-supplementation on glycemic control and lipid concentrations in patients with gestational diabetes. J Clin Lipidol 2017, 11(2):459-468.
Chen C, Yang Y, Yu X, Hu S, Shao S: Association between omega-3 fatty acids consumption and the risk of type 2 diabetes: A meta-analysis of cohort studies. J Diabetes Investig 2017, 8(4):480-488.
Akhigbe RE, Hamed MA, Odetayo AF, Akhigbe TM, Ajayi AF, Ajibogun FAH: Omega-3 fatty acid rescues ischaemia/perfusion-induced testicular and sperm damage via modulation of lactate transport and xanthine oxidase/uric acid signaling. Biomed Pharmacother 2021, 142:111975.
Saito H, Toyoda Y, Takada T, Hirata H, Ota-Kontani A, Miyata H, Kobayashi N, Tsuchiya Y, Suzuki H: Omega-3 Polyunsaturated Fatty Acids Inhibit the Function of Human URAT1, a Renal Urate Re-Absorber. Nutrients 2020, 12(6).
Limirio LS, Santos HO, Dos Reis AS, de Oliveira EP: Association Between Dietary Intake and Serum Uric Acid Levels in Kidney Transplant Patients. J Ren Nutr 2021, 31(6):637-647.
Lin KC, Lin HY, Chou P: Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kinmen. J Rheumatol 2000, 27(4):1045-1050.
Paulose-Ram R, Burt V, Broitman L, Ahluwalia N: Overview of Asian American Data Collection, Release, and Analysis: National Health and Nutrition Examination Survey 2011-2018. Am J Public Health 2017, 107(6):916-921.
Zhang R, Sun J, Li Y, Zhang D: Associations of n-3, n-6 Fatty Acids Intakes and n-6:n-3 Ratio with the Risk of Depressive Symptoms: NHANES 2009-2016. Nutrients 2020, 12(1).
Rathmann W, Haastert B, Icks A, Giani G, Roseman JM: Ten-year change in serum uric acid and its relation to changes in other metabolic risk factors in young black and white adults: the CARDIA study. Eur J Epidemiol 2007, 22(7):439-445.
Limirio LS, Santos HO, Dos Reis AS, de Oliveira EP: Association Between Dietary Intake and Serum Uric Acid Levels in Kidney Transplant Patients. J Ren Nutr 2021.
Chen J, Sun B, Zhang D: Association of Dietary n3 and n6 Fatty Acids Intake with Hypertension: NHANES 2007-2014. Nutrients 2019, 11(6).
Bercea CI, Cottrell GS, Tamagnini F, McNeish AJ: Omega-3 polyunsaturated fatty acids and hypertension: a review of vasodilatory mechanisms of docosahexaenoic acid and eicosapentaenoic acid. Br J Pharmacol 2021, 178(4):860-877.
Messerli FH, Frohlich ED, Dreslinski GR, Suarez DH, Aristimuno GG: Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Ann Intern Med 1980, 93(6):817-821.
Fedor D, Kelley DS: Prevention of insulin resistance by n-3 polyunsaturated fatty acids. Curr Opin Clin Nutr Metab Care 2009, 12(2):138-146.
Drouin-Chartier JP, Tremblay AJ, Lépine MC, Lemelin V, Lamarche B, Couture P: Substitution of dietary ω-6 polyunsaturated fatty acids for saturated fatty acids decreases LDL apolipoprotein B-100 production rate in men with dyslipidemia associated with insulin resistance: a randomized controlled trial. Am J Clin Nutr 2018, 107(1):26-34.
Artunc F, Schleicher E, Weigert C, Fritsche A, Stefan N, Häring HU: The impact of insulin resistance on the kidney and vasculature. Nat Rev Nephrol 2016, 12(12):721-737.
Park JH, Jo YI, Lee JH: Renal effects of uric acid: hyperuricemia and hypouricemia. Korean J Intern Med 2020, 35(6):1291-1304.
Dalbeth N, Wong S, Gamble GD, Horne A, Mason B, Pool B, Fairbanks L, McQueen FM, Cornish J, Reid IR et al: Acute effect of milk on serum urate concentrations: a randomised controlled crossover trial. Ann Rheum Dis 2010, 69(9):1677-1682.
Garrel DR, Verdy M, PetitClerc C, Martin C, Brulé D, Hamet P: Milk- and soy-protein ingestion: acute effect on serum uric acid concentration. Am J Clin Nutr 1991, 53(3):665-669.
Ghadirian P, Shatenstein B, Verdy M, Hamet P: The influence of dairy products on plasma uric acid in women. Eur J Epidemiol 1995, 11(3):275-281.
Huang HY, Appel LJ, Choi MJ, Gelber AC, Charleston J, Norkus EP, Miller ER, 3rd: The effects of vitamin C supplementation on serum concentrations of uric acid: results of a randomized controlled trial. Arthritis Rheum 2005, 52(6):1843-1847.
Zhang YY, Qiu HB, Tian JW: Association Between Vitamin D and Hyperuricemia Among Adults in the United States. Front Nutr 2020, 7:592777.
Villegas R, Xiang YB, Elasy T, Xu WH, Cai H, Cai Q, Linton MF, Fazio S, Zheng W, Shu XO: Purine-rich foods, protein intake, and the prevalence of hyperuricemia: the Shanghai Men's Health Study. Nutr Metab Cardiovasc Dis 2012, 22(5):409-416.
Sun Y, Sun J, Zhang P, Zhong F, Cai J, Ma A: Association of dietary fiber intake with hyperuricemia in U.S. adults. Food Funct 2019, 10(8):4932-4940.
Zhang Y, Qiu H: Dietary Magnesium Intake and Hyperuricemia among US Adults. Nutrients 2018, 10(3).
Zhang Y, Liu Y, Qiu H: Association between Dietary Zinc Intake and Hyperuricemia among Adults in the United States. Nutrients 2018, 10(5).
Cholewski M, Tomczykowa M, Tomczyk M: A Comprehensive Review of Chemistry, Sources and Bioavailability of Omega-3 Fatty Acids. Nutrients 2018, 10(11).
De Becker B, Borghi C, Burnier M, van de Borne P: Uric acid and hypertension: a focused review and practical recommendations. J Hypertens 2019, 37(5):878-883.
Tanaka K, Ogata S, Tanaka H, Omura K, Honda C, Hayakawa K: The relationship between body mass index and uric acid: a study on Japanese adult twins. Environ Health Prev Med 2015, 20(5):347-353.
Fabregat I, Revilla E, Machado A: Short-term control of the pentose phosphate cycle by insulin could be modulated by the NADPH/NADP ratio in rat adipocytes and hepatocytes. Biochem Biophys Res Commun 1987, 146(2):920-925.

No competing interests reported.

SupplementaryTable1.docx

Download PDF

Version 1

posted

You are reading this latest preprint version

Inverse Association of Dietary Consumption of n3 and n6 Fatty Aids with Hyperuricemia among Adults

Status:

Version 1

Abstract

Background

Materials and methods

Results

Conclusion

Figures

Introduction

Materials and methods

Study population

Serum uric acid measurement and definitions of hyperuricemia

The dietary consumption of n3 and n6 fatty acids

Covariates

Statistical analysis

Results

1, Baseline characteristics

2, Associations between dietary consumption of n3 and n6 fatty acids and hyperuricemia

3, Consumption of N3 and n6 fatty acids stratified by age

4, Consumption of N3 and n6 fatty acids stratified by sex

5, Sensitivity analyses

6, Dose‒response analyses

Discussion

Conclusion

Declarations

References

Additional Declarations

Supplementary Files

Status:

Version 1